Outsourcing

Jon Sutch, PhD, is manager of formulation development at Patheon’s Milton Park facility, UK, jon.sutch@patheon.com.

Articles

Despite the growth of specialist companies with capabilities across various therapeutic areas in Europe, there is still a need for early development expertise with end-to-end pharmaceutical manufacturing capabilities.

Europe's Need for Early Development Pharmaceutical Manufacturing Expertise

Contract development and manufacturing organizations identify trends, challenges, and emerging technology and service needs for solid and semi-solid dosage forms.

Solid-Dosage Forms Demand Traditional and Emerging Technologies

Rita Peters is the former editorial director of 

Pharmaceutical Technology, Pharmaceutical Technology Europe

For a bio/pharma industry in flux, contract services are playing a greater-and more diverse-role in drug development.

Shifting Gears in Drug Development Outsourcing Responsibilities

Hovione will use Merrion's GIPET absorption-enhancing technology for solid-dosage drugs.

Hovione Partners with Merrion Pharmaceuticals on Absorption-Enhancing Technology

PharmSource special report shows demand for cytotoxic injectable drugs could tap existing CMO capacity.

Pharma Capacity to Produce Cytotoxic Injectable Drugs Constricts

Michael Kuchenreuther, PhD, is a research analyst, at Numerof & Associates, Inc.

Jill E. Sackman, PhD, is a senior consultant at Numerof & Associates, Inc. (NAI), St. Louis, MO, www.nai-consulting.com.

Biopharma companies should not overlook India's growing market.

India's Developing Market Offers Opportunities

The international pharmaceutical industry is changing its approach to R&D and is increasingly relying on outsourcing for drug discovery.

Drug Discovery Partnerships between UK CROs and the Swiss Pharma Sector

Eric Langer has over 25 years experience in biotechnology and life sciences strategic marketing management, market research, and publishing. He has held senior management and marketing positions at biopharmaceutical supply companies. He has published and authored many books and reports on topics in Biotechnology, Large-scale BioManufacturing, and bioscience commercialization and communication. He teaches at Johns Hopkins University marketing management, biotech marketing, services marketing, and marketing in a regulated environment. In 1989 he co-founded BioPlan Associates, Inc. to provide market analysis, and strategy to biotech and healthcare organizations.

CMOs may find opportunities in alternative expression services.

Novel Expression Systems Opening CMO Opportunities

Janis Hall is a senior consultant at The Avoca Group

The relatively low success rates for bio/pharmaceutical compounds in clinical development have prompted many organizations to explore ways of reducing risk in clinical development.

Managing Clinical Development Risk: Pharma and CRO Report

Regis Technologies passes a recent FDA audit with no Form 483 observations.

Contract Development Services